FAT1 and neoplasm: Tumor sites were significantly different between the FAT1‐LR and FAT1‐HR subgroups (oral cavity 44.47% vs. 67.47%; oropharynx 31.54% vs. 11.51%; P = 2.2e−16; Table S6).